Ofatumumab

CAS No. 679818-59-8

Ofatumumab( —— )

Catalog No. M22156 CAS No. 679818-59-8

Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 558 In Stock
10MG 805 In Stock
25MG 1226 In Stock
50MG 1609 In Stock
100MG 2167 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ofatumumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation.
  • Description
    Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Other Targets
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    679818-59-8
  • Formula Weight
    149 kDa
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Barth MJ, et al.Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.Clin Cancer Res. 2015 Oct 1;21(19):4391-7.
molnova catalog
related products
  • Vitamin K1

    A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain.

  • CJ-42794

    CJ-42794 is a selective antagonist of prostaglandin E receptor subtype 4 (EP4). It inhibits [3H]-PGE2 binding to the human EP4 receptor (a mean pKi: 8.5).

  • Swainsonine

    Swainsonine (Tridolgosir) is an natural indolizidine alkaloid, a potent and reversible α-mannosidase inhibitor. Swainsonine induces apoptosis and cell cycle arrest at G2/M phase. Swainsonine shows anti-tumor activity.